

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Weitnauer *et al.*

Serial No.: 10/084,846

Filed: February 25, 2002

Atty Dkt: 1974.005

Group Art Unit:

Examiner:

Title: AVILAMYCIN DERIVATIVES



Certificate of Mailing Under 37 CFR §1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on May 7, 2002.

*Candice J. Clement*

Candice J. Clement

Attorney for Applicants

Reg. No. 39,946

Date of Signature: May 7, 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

**SUPPLEMENTAL PRELIMINARY AMENDMENT UNDER 37 CFR 1.115**

Dear Sir:

This paper is not filed in response to any Office Communication, but for the purpose of correcting two typographic errors in the above-referenced specification.

1. Please replace Paragraph 70

The amount of active substance to be administered to the patient varies as a function of the patient's weight, the method of administration, the indication and the degree of severity of the illness. Usually, 0.005 to 1,000 mg/kg, preferably 0.05 to 5 mg/kg of at least one avilamycin derivative are administered.

2. Please replace Paragraph 107

Gavibamycin B1 and B3 correspond to the general Formula I, with the following significance for the moieties R1-R9:

No.	R1	R2	R3	R4	R5	R6	R7	R8	R9
B1	COCH(CH <sub>3</sub> ) <sub>2</sub>	COCH <sub>3</sub>	OH	H	H	CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>
B3	COCH(CH <sub>3</sub> ) <sub>2</sub>	CH(OH)CH <sub>3</sub>	OH	H	H	CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>

Example 8 Biological properties of gavibamycin A3

**Amended Paragraphs 70 and 107 with markings to show changes made**

1. Paragraph 70 is amended:

The amount of active substance to be administered to the patient varies as a function of the patient's weight, the method of administration, the indication and the degree of severity of the illness. Usually, 0.005 to 1,000 mg/kg, preferably [0.5] **0.05** to 5 mg/kg of at least one avilamycin derivative are administered.

2. Paragraph 107 is amended:

Gavibamycin B1 and B3 correspond to the general Formula I, with the following significance for the moieties R1-R9:

No.	R1	R2	R3	R4	R5	R6	R7	R8	R9
B1	COCH(CH <sub>3</sub> ) <sub>2</sub>	COCH <sub>3</sub>	OH	[Cl] H	[Cl] H	CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>
B3	COCH(CH <sub>3</sub> ) <sub>2</sub>	CH(OH)CH <sub>3</sub>	OH	[Cl] H	[Cl] H	CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>

**Example 8** Biological properties of gavibamycin A3